June 23, 2021
Chasing ‘Holy Grail’ STAT3 Target, Houston Startup Refuels with $74M to Zero in on Liver Cancer

June 23, 2021
Tvardi Raises $74M to Advance STAT3 Inhibitors for Cancer, Fibrosis

June 23, 2021
Houston-Based Tvardi Therapeutics Raises $74 Million in Series B Funding

June 22, 2021
Tvardi Snags $74M to Weed the Tumor Garden with STAT3 Inhibitor


November 20, 2020
Tvardi Therapeutics Awarded Most Promising Company

June 03, 2020
KRLD Radio Interview: Some Covid Survivors Face Long-Term Consequences

May 20, 2020
Why Overcoming Covid-19 is Just the First Hurdle of a Much Longer Journey: Irreversible Lung Scarring Possible in Survivors


April 10, 2019
Tvardi Therapeutics CEO Imran Alibhai Talks Biotech

January 02, 2019
Biotech on the Rise


December 12, 2018
Former M.D. Anderson president’s new Houston company names first CEO

December 12, 2018
Tvardi Therapeutics Names Imran Alibhai Chief Executive Officer

September 27, 2018
Tvardi, Co-Founded by Former MD Anderson Leader DePinho, Raises $9M

September 21, 2018
Tvardi Therapeutics, Inc. Secures $9 Million in Series A Financing Round

September 20, 2018
Former M.D. Anderson president’s new Houston company secures funding, seeks CEO

September 20, 2018
Tvardi Therapeutics raises $9M series A for STAT3 inhibitors

Uncategorized Archives - Tvardi Top